OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.
OncoResponse has raised $14.0M in total funding. The most recent round was Series D. The last funding was announced in May 2023.
OncoResponse's investors include Rice University, Redmile Group, ARCH Venture Partners, GreatPoint Ventures, Canaan Partners.
OncoResponse is headquartered in Seattle, United States.
OncoResponse is an immuno-oncology biotech company developing cancer immunotherapies leveraging human immune system responses.
OncoResponse is at the Series D stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"OncoResponse — Funding & Investors." VCBacked, May 18, 2023, https://www.vcbacked.co/company/oncoresponse. Accessed July 20, 2026.
VCBacked. (2023). OncoResponse — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/oncoresponse
{{cite web |title=OncoResponse — Funding & Investors |url=https://www.vcbacked.co/company/oncoresponse |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated